ArticleFrontiers in aging neuroscience2026
Plasma chaperone-mediated autophagy associated protein HSPA8 combined with white matter hyperintensities serves as the predictive marker of early-stage Alzheimer's disease.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The relationship between plasma chaperone-related autophagy proteins and white matter hyperintensity (WMH) in Alzheimer's disease (AD) remains unclear. Methods: We employed 4D-DIA proteomics to identify plasma protein changes, and evaluated the clinical relevance of the chaperone-mediated autophagy (CMA)-related protein HSPA8. Additionally, using ITK-SNAP software to assess WMH volume's role in AD. We analyzed the ROC curves for both HSPA8 and WMH in the AD spectrum. Among which, using One-Anova, Kruskal-Wallis, and multivariable logistic analyses to detect the population data. Moreover, the impact of age on WMH volume changes between the AD group and the CN group will be assessed using sensitivity analysis and testing the age-diagnosis interaction. Results: Significant factors in the AD population included age, MMSE score, MoCA score, and WMH volumes. The OR for age in MCI and for WMH volume in AD patients were significant. The expression of HSPA8 was decline in the AD disease spectrum, but it had no statistical difference. Importantly, HSPA8 protein had the highest AUC value for distinguishing between cognitively normal (CN)/mild cognitive impairment (MCI) and MCI/AD groups. Meanwhile, WMH was significant in the AD disease spectrum. And the influence of age on WMH is comparable in cognitively normal elderly individuals and those with AD. Combining HSPA8 with WMH improved the AUC value, which was further enhanced by including age and gender. Conclusion: We found that the level of CMA-related protein HSPA8 is decline in the AD disease continuum, and WMH volume may help differentiate the AD spectrum. Moreover, Age is the primary factor influencing WMH changes in both CN and AD groups, with AD status having no significant effect on WMH levels or their progression. Thus, age should be carefully considered when evaluating elevated WMH in AD patients. It is noteworthy that the integration of HSPA8 and WMH may function as a potential early biomarker for AD, thereby enhancing the accuracy of its early diagnosis. Including age and gender increases the diagnostic model's AUC value, indicating HSPA8 and WMH are crucial for early AD diagnosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.